Agenus (AGEN) vs Scribe Therapeutics (SCTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Scribe Therapeutics is the larger company by market cap ($364.1 million vs $340.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGEN | SCTX |
|---|---|---|
| Share price | $7.54 | $19.23 |
| Market cap | $340.52M | $364.06M |
| 1-day change | -0.40% | +9.45% |
| YTD return | +140.13% | — |
| 1-year return | +80.82% | — |
| 5-year return | -92.77% | — |
| P/E ratio (TTM) | 2.98 | — |
| EPS (TTM) | $2.53 | $-3.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.31 | $39.60 |
| 52-week low | $2.71 | $13.50 |
| Distance from 52-week high | -26.87% | -51.44% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +249.20% | +196.41% |
| Average volume | 4.26M | 357.40K |
| Shares outstanding | 45.16M | 18.93M |
| Employees | 81 | 82 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Agenus
AGEN stock →Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Healthcare · Biotechnology · 81 employees
About Scribe Therapeutics
SCTX stock →Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.
Healthcare · Biotechnology · 82 employees
AGEN vs SCTX FAQ
Which is bigger, Agenus or Scribe Therapeutics?
Scribe Therapeutics (SCTX) is larger, with a market capitalization of $364.06M compared with $340.52M for Agenus (AGEN).
Are Agenus and Scribe Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.